[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100645368":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":43,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":10,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":52,"minAge":53,"maxAge":10,"enrollmentInfo":54,"targetDuration":10,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Physicians treating MASLD",null,"The survey will be conducted via 15-minute online questionnaire survey of 30 specialists in the departments of endocrinology, hepatology, infection, and gastroenterology.",[13],"Other: No treatment is given",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"OTHER","No treatment is given","This study is a cross-sectional survey-based study. The design is observational and descriptive. Collection of data will be performed via a quantitative online survey.",[9],[21],{"name":22,"affiliation":5,"role":23},"Clinical Transparency (dept. 2834)","STUDY_DIRECTOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Novo Nordisk","CONTACT","(+1) 866-867-7178","clinicaltrials@novonordisk.com",[31],{"facility":32,"status":33,"city":34,"state":10,"zip":10,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Novo Nordisk Investigational site","RECRUITING","Beijing","China","CN",{"type":38,"coordinates":39},"Point",[40,41],116.39723,39.9075,{"lat":41,"lon":40},{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100645368",false,"NCT07682363","Management Concepts of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) Among Chinese Physicians","Attitudes, Perceptions, Clinical Practice, and Barriers in Diagnosis and Management of Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: a Cross-sectional Survey on Physicians in China","Inclusion Criteria:\n\n* Has provided informed consent.\n* Registered clinical practice location in provincial capital or municipality.\n* Physician with a license for clinical practice.\n* Employed in the Department of Endocrinology, Hepatology, Infection or Gastroenterology.\n* Hospital level: Grade IIIA hospital.\n* Hold a professional title of associate chief physician or above, or senior attending physician (as an attending physician for more than or equal to (≥) 3 years).\n* Conducts outpatient clinics for at least 1 half-days per week.\n* The patient load of MASLD\u002FMASH per month in the department should be:\n* a. Endocrinology ≥20 patients per month\n* b. Hepatology\u002FGastroenterology\u002F Infectious ≥30 patients per month\n\nExclusion Criteria:\n\n-Participants will be excluded if they have unwillingness precluding adequate cooperation, fail to complete the questionnaire, or submit questionnaires verified as invalid.",true,"ALL","18 Years",{"count":55,"type":56},470,"ESTIMATED","OBSERVATIONAL","This study is a cross-sectional survey-based study. The main goal of this study is to investigate the attitudes, perceptions, and clinical practice in assessing liver fibrosis following a metabolic dysfunction-associated steatotic liver disease (MASLD) diagnosis, and the management of MASLD patients among Chinese physicians in the departments of endocrinology \u002F hepatology \u002F infection \u002F gastroenterology in Grade IIIA hospitals in provincial capitals or municipalities.",[60],"Liver Disease","2026-06-26",{"date":63,"type":64},"2026-07-02","ACTUAL",{"date":66,"type":64},"2026-06-03",{"date":68,"type":56},"2027-02-23",{"name":5,"class":6},1]